An Expert View from Dr Elena Wolff-Holz, global head of clinical development at Biocon Biologics, the biosimilar subsidiary ...

Biosimilars offer affordable medical treatments, but regulatory guidelines need updating to ensure safety, efficacy, and ...

More ‘biosimilar’ medicines should be brought to market in the EU because of a regulatory policy shift on the need to carry ...

India needs to update its biosimilar regulations to ensure safe, effective, and affordable medicines, balancing quality and cost for better patient care.

GlobalData’s Emerging Market Outsourcing report reveals that this push for domestic production could lead to increased ...

Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

By 2023, approximately 1 in 5 patients with non-small cell lung cancer or metastatic colorectal cancer were treated with a bevacizumab biosimilar.

No matter how high the inflation is, their demand is inelastic. No matter how slow the current profit growth is, these ...

Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...

Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in ...

CVS Caremark, Express Scripts and Optum Rx — the three largest pharmacy benefit managers in the U.S. — each excluded more ...